Search

Background: Diabetes reduces the activity of CYP3A4 and may increase the exposure for the drugs metabolized by the isoenzyme. Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI), used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma and radioactive iodine resistant thyroid carcinoma. The TKI undergoes CYP3A4-dependent oxidative transformation, which may be influenced by hyperglycaemia. The aim of the study was to compare the oxidation for sorafenib between healthy and streptozotocin-induced diabetic rats. Additionally, the effect of sorafenib on glucose levels was investigated. Methods: The rats were assigned to the groups: streptozotocin-induced diabetic (DG, n?=?8) or healthy (HG, n?=?8). The rats received sorafenib orally as a single dose of 100 mg/kg. The plasma concentrations of sorafenib and its metabolite N-oxide were measured with the validated high-performance liquid chromatography with ultraviolet detection. Results: The difference between groups in Cmaxand AUC0-tvalues for sorafenib were significant (p?=?0.0004, p?=?0.0104), and similarly for the metabolite (p?=?0.0008, p?=?0.0011). Greater exposure for the parent drug and analysed metabolite was achieved in diabetic group. However, the Cmax, AUC0-t, and AUC0-8ratios between the metabolite and sorafenib were similar in both groups. The significant reduction of glycaemia was observed only in the diabetic animals. Conclusion: The findings of the study provide evidence that diabetes significantly influence on the exposition for sorafenib and its metabolite, but similar ratios N-oxide/sorafenib for AUC and Cmaxin healthy and diabetic animals suggest that oxidation of the TKI is rather unchanged. Additionally, sorafenib-associated hypoglycaemia was confirmed in diabetic animals.

The combined use of tramadol with selective serotonin and norepinephrine reuptake inhibitors e.g. venlafaxine may be associated with serotonin syndrome. No previous studies exist examining the influence of a weak CYP2D6 inhibitor venlafaxine on the pharmacokinetics of tramadol. Therefore, the aim of this study was to determine the effect of a single and chronic administration of venlafaxine on the pharmacokinetics of tramadol using a rabbit model.

Background: Macrolides are the most widely prescribed antibiotics. Clarithromycin is a well-known inhibitor of cytochrome P450 CYP3A4 and causes numerous drug interactions that are not found for azithromycin. CYP3A4 is involved in the metabolism of the new oral multikinase inhibitor sunitinib and its active N-desethyl metabolite (SU012662). This study investigated the effects of oral single dose of clarithromycin or azithromycin on the pharmacokinetics of sunitinib. Methods: Rabbits were subjected to one of three study drug groups: sunitinib + clarithromycin (n = 6), sunitinib + azithromycin (n = 6), or sunitinib (n = 6). The rabbits were treated with sunitinib in the oral dose of 25 mg. Plasma concentrations of sunitinib were measured with validated HPLC method with UV detection. Results: Comparison of the sunitinib Cmaxfor the sunitinib + clarithromycin group with that of the sunitinib group gave a ratio of 94.4% [90% confidence interval (CI) (76.1, 117.1)]; for the sunitinib + azithromycin group, the ratio was 106.2% (90% CI 85.5, 131.7). Comparison of the sunitinib AUC0-tof the sunitinib + clarithromycin and sunitinib + azithromycin groups with that of the sunitinib group showed ratios of 86.86% (90% CI 69.7, 108.3) and 99.8% (90% CI 80.1, 124.5), respectively. Conclusions: No significant effect of the coadministration of clarithromycin or azithromycin on the pharmacokinetics of sunitinib in rabbits was found in this study.

We synthesized a 2-N-methylaminoethyl-tetramethylquanidine amide of Kemp's triacid (CP2). Furthermore, we added to CP2 tetrabutylammonium 4-tert-butylpenolate. The pKavalue of 4-tert-butylphenol is comparable to that of tyrosine. We studied by FT-IR spectroscopy CP2 and the complex of CP2 with 4-tert-butylphenolate. This complex is a model for the hydrogen-bonded chain in the active centre of the bacteriorhodopsin molecule. An intense continuum in the FT-IR spectra demonstrates that this hydrogen-bonded chain shows large proton polarizability due to collective proton motion. As earlier demonstrated also Schiff base carboxylic acid bonds show large proton polarizability. Thus, in all these hydrogen bonds protons can easily be shifted by collective proton motion due to changes of the local electrical fields and by changes of specific interactions arising from conformational changes.

We synthesized a triamide of Kemp's acid with two cysteine groups and one histidine group (compound 1), and a triamide of 1,3,5-pentane tricarboxylic acid with tyrosine, histidine, and arginine molecules (compound 2). From compound 1 we obtained the hydrated Zn2+complex, compound 3. The FT-IR spectra of various complexes of compounds 1–3 with NAD+show no IR continua and hence, no hydrogen-bonded chains with proton polarizability are present. In the case of the complex (compounds 2 and 3 and NAD+) an intense continuum demonstrates that a hydrogen-bonded chain is formed with large proton polarizability due to collective proton motion. This proton pathway is discussed. The O atom of the nicotinamide group of NAD+is a strong hydrogen bond acceptor. This result is discussed with regard to the catalytic mechanism.

The mono- as well as the di-Mannich bases of 5,5′-dimethoxy-2,2′-biphenol are studied by FT-IR spectroscopy. It is shown that in these bases the protons remain localized at the phenol O atom. This result is in contrast to those obtained earlier for more acidic biphenols in which the protons are not localized but fluctuate and the relevant hydrogen bonds show large polarizability. An intense infrared continuum in the FT-IR spectrum of the mono-protonated di-Mannich base of 5,5′-dimethoxy-2,2′-biphenol demonstrates that the intramolecular hydrogen bond in this compound shows large proton polarizability.

A correction to this paper has been published: https://doi.org/10.1007/s43440-021-00278-4